PTC Therapeutics, Inc. (PTCT) Financial Analysis & Valuation | Quarter Chart
PTC Therapeutics, Inc. (PTCT)
PTCTPrice: $81.57
Fair Value: 🔒
🔒score
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinica... more
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and comm... more
Description
Shares
| Market Cap | $6.77B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Matthew Klein |
| IPO Date | 2013-06-20 | CAGR | 0.23% |
| Employees | 939 | Website | www.ptcbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PTCT chart loading...
Fundamentals
Technicals
| Enterprise Value | $6.36B | P/E Ratio | -35.01 |
| Forward P/E | 29.31 | PEG Ratio | — |
| P/S Ratio | 135.79 | P/B Ratio | -620.09 |
| P/CF Ratio | -513.5 | P/FCF Ratio | -491.38 |
| EPS | $-2.33 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -53.34% | Gross Margin | 0.78% |
| Operating Margin | -0.08% | Profit Margin | -0.23% |
| ROE | 1% | ROA | -0.07% |
| ROCE | -0.03% | Current Ratio | 2.44 |
| Quick Ratio | 2.36 | Cash Ratio | 0.9 |
| Debt/Equity | -2.19 | Interest Coverage | -0.98 |
| Altman Z Score | 0.67 | Piotroski Score | 1 |